Rare Disease Medical
Communications India.

Rare disease — the evidence-narrative discipline

Rare disease medical communications operates under fundamentally different rules from high-prevalence therapeutic areas. Patient populations are small; clinical trials have limited statistical power; randomised controlled trials are often impossible or unethical (a rare-disease patient denied access to an investigational therapy may have no alternative). The regulatory narrative must compensate for data limitations with rigorous literature context, mechanistic plausibility arguments, and natural-history-of-disease evidence.

India's orphan drug regulatory framework

India's orphan drug regulatory framework is evolving. The National Policy for Rare Diseases (2021, revised) defines three categories of rare disease (Group 1 — one-time curative treatment; Group 2 — long-term/lifelong management; Group 3 — ultra-high-cost therapies). The CDSCO has accelerated-approval pathways for orphan drugs but requires post-approval real-world evidence commitments. ICG's rare disease engagements include the post-approval evidence-generation strategy from Day 1 — the rare-disease brand that fails post-approval evidence commitments loses approval.

Mechanistic plausibility — the evidence-bridging argument

Rare disease HCP audiences (rare-disease consultants, specialist geneticists, paediatric specialists) are highly familiar with both the rare disease itself and the underlying mechanism. ICG's rare disease scientific writing emphasises mechanistic plausibility: if Drug X targets pathway Y, and Y is mechanistically linked to disease Z, the limited clinical evidence is interpretable within a coherent biological framework. The mechanistic argument is what bridges from limited trial data to clinical confidence.

Patient advocacy groups — the active participants

Rare disease patient advocacy groups in India (Organization for Rare Diseases India — ORDI, Lysosomal Storage Disorders Support Society, and disease-specific groups) play an unusually active role in treatment decisions, regulatory engagement, and pricing policy advocacy. ICG's rare disease brand engagements treat these groups as primary stakeholders — not afterthoughts. Patient-advocacy-group content is built to the same scientific standard as HCP content, with the appropriate translation for lay audiences.

Outcome targets

(1) Post-approval evidence-commitment delivery — measurable against CDSCO commitments. (2) Specialist HCP engagement quality — measurable via rare-disease consultant surveys. (3) Patient advocacy engagement — measurable via participation in advocacy-group programmes. (4) Real-world evidence registry growth — measurable via Pharos Pulse-integrated registry data.